Related Experiment Video
Updated: Jun 12, 2025
05:23
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
19.4K
How We Treat Hemolytic Anemia Due to Pyruvate Kinase Deficiency.
Sara Tama-Shekan1, Valeria Moreno1, Ludovic Saba1
1Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
Hematology Reports
|September 23, 2024
Summary
Mitapivat effectively treats pyruvate kinase (PK) deficiency anemia in most patients, improving hemoglobin and reducing transfusions. However, not all individuals with PK deficiency respond to this disease-modifying medication.
Area of Science:
- Hematology
- Genetics
- Pharmacology
Background:
- Pyruvate kinase (PK) deficiency is a genetic disorder causing chronic hemolytic anemia in red blood cells (RBCs).
- Symptoms include anemia, fatigue, jaundice, and potential complications like gallstones and iron overload.
- Current management focuses on symptomatic relief and RBC transfusions.
Observation:
- Mitapivat, an oral activator of PK enzymes, is a novel treatment for PK deficiency.
- This study examined three cases of PK deficiency treated with mitapivat.
- A retrospective healthcare database analysis was used to gather information.
Findings:
- Two out of three patients showed positive responses to mitapivat, with increased hemoglobin and reduced transfusion needs.
- One patient with specific non-missense PKLR gene mutations did not respond to mitapivat.
- Treatment response varied based on patient-specific factors, including genotype.
Implications:
- Mitapivat represents a significant advancement as a disease-modifying therapy for PK deficiency.
- Genotype and phenotype assessments are crucial for optimizing mitapivat treatment decisions.
- Further research may identify patient subgroups who benefit most from mitapivat therapy.
Related Concept Videos
01:20Fates of Pyruvate
8.4K
Pyruvate is the end product of glycolysis, where glucose is oxidized to pyruvate, simultaneously reducing NAD+ to NADH. Two molecules of ATP are also produced by substrate-level phosphorylation.
In aerobic organisms, pyruvate is metabolized via the citric acid cycle to produce reduced coenzymes NADH and FADH2. These coenzymes are then oxidized in the electron transport chain to produce ATP and, in the process, regenerate the NAD+ and FAD. As seen in some cell types and organisms, fermentation...
In aerobic organisms, pyruvate is metabolized via the citric acid cycle to produce reduced coenzymes NADH and FADH2. These coenzymes are then oxidized in the electron transport chain to produce ATP and, in the process, regenerate the NAD+ and FAD. As seen in some cell types and organisms, fermentation...
8.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
146
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
146
01:24Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235
01:22Bone Marrow Sampling and Transplants
313
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
313
01:19Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K